Curis, Inc. · NASDAQ:CRIS

Curis — Investor Presentation (September 2023)

16 slides from Curis's investor presentation, September 2023

  1. Slide 1: Corporate Presentation

    Corporate Presentation NASDAQ: CRIS © 2023 Curis, Inc.

  2. Slide 2: Cautionary Note Regarding Forward Looking Statements and Disclaimers

    Cautionary Note Regarding Forward Looking Statements and Disclaimers This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “beli

  3. Slide 3: Corporate Overview

    Corporate Overview Leader of IRAK4 Inhibition in Oncology; Developing Emavusertib with Broad Hematological Applications Investment Emavusertib is a highly-active inhibitor with potential to be the cornerstone agent in hematologic malignancies Thesis Cash runway into 2025 – Proforma cash of $77.4M as

  4. Slide 4: Emavusertib in Leukemia (AML/MDS)

    Emavusertib in Leukemia (AML/MDS)

  5. Slide 5: Emavusertib has a Unique Molecular Fingerprint

    Emavusertib has A Unique Molecular Fingerprint The NCI selected emavusertib for Targeted design is specifically engineered to be best-in-class NCI-sponsored research and clinical studies of IRAK4 Emavusertib Emavusertib Kinase Interaction Map Binding Affinity FLT3 Target Kd nM IRAK4 IRAK1 12,000 IRA

  6. Slide 6: Emavusertib Has a Unique Mechanism of Action

    Emavusertib Has a Unique Mechanism of Action The two primary targets of emavusertib are independent drivers of cancer IRAK4 FLT3 spliceosome mutations drive overexpression of IRAK4-Long, which genetic mutations cause constitutive activation of FLT3 constitutively activates the myddosome, driving NF-

  7. Slide 7: Preclinical Data

    Preclinical Data Rationale for monotherapy and combination with azacitidine/venetoclax Monotherapy in IRAK4 Monotherapy in FLT3 Combination with Aza/Ven 100% “Concomitant targeting of IRAK1 or IRAK4, alongside FLT3, is the most effective means to overcome the adaptive resistance incurred when target

  8. Slide 8: Compelling Initial Clinical Data

    Emavusertib Compelling Initial Clinical Data Showing clear single agent activity where expected in clinical studies 84 AML/MDS Patients 8 AML Patients 7 AML Patients all comers, all dose levels Spliceosome Mutation* with FLT3 Mutation* 100% ** ** ** 80% % Change in Marrow Blast from Baseline 0% 0% 6

  9. Slide 9: Potential Cornerstone Treatment for Hematologic Malignancies

    Potential Cornerstone Treatment for Hematologic Malignancies Emavusertib inhibits both IRAK4 and FLT3 – key disease drivers in leukemia and lymphoma Monotherapy targets the two Emavusertib synergizes with existing AML/MDS Leukemia largest genetically-defined patient treatments5 as IRAK4-L is express

  10. Slide 10: Emavusertib in Leukemia (AML/MDS)

    Emavusertib in Leukemia (AML/MDS) The ideal candidate to address the two largest genetically-defined populations in AML/MDS Emavusertib addresses the two largest genetically-defined populations in AML/MDS: 1 1) IRAK4-L (>50% of population) 2 2) FLT3 (>25% of population) Next Steps TakeAim Leukemia S

  11. Slide 11: Emavusertib in Lymphoma (NHL/CLL)

    Emavusertib in Lymphoma (NHL/CLL)

  12. Slide 12: Emavusertib in Lymphoma

    Emavusertib in Lymphoma Combination therapy provides complimentary inhibition of two pathways that drive NF-κB NFκB Biology: Clinical Strategy: Two Pathways Drive NHL/CLL Block both pathways with Combination Therapy BCR and TLR Pathways independently drive NF-κB overactivity In preclinical testing,

  13. Slide 13: Initial Clinical Data in Lymphoma

    Initial Clinical Data in Lymphoma Majority of patients achieved decreases in tumor burden, including complete responses NHL/CLL 100% Change in Tumor Burden Over Time combination with ibrutinib combination with ibrutinib 80% 60% % Change in Tumor Burden from Baseline 40% 20% BTK-naïve BTK-experienced

  14. Slide 14: Clinical Strategy in Lymphoma

    Clinical Strategy in Lymphoma The ideal candidate to combine with BTKi to maximize downregulation of NF-κB • Patients are currently treated with BTKi because it downregulates NF-κB • Two pathways drive NF-κB: Next Steps TakeAim Lymphoma Study 1) BCR Pathway: addressed by blocking BTK 2) TLR Pathway:

  15. Slide 15: Corporate Overview

    Corporate Overview Leader of IRAK4 Inhibition in Oncology; Developing Emavusertib with Broad Hematological Applications Investment Emavusertib is a highly-active inhibitor with potential to be the cornerstone agent in hematologic malignancies Thesis Cash runway into 2025 – Proforma cash of $77.4M as

  16. Slide 16: End of Corporate Presentation

    End of Corporate Presentation NASDAQ: CRIS

Curis — Investor Presentation (September 2023) on 6ix